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ImmunologyAims: There is increasing evidence on the role of helminth infections in modifying autoim-
mune and allergic diseases. These infections may have similar effect in other inflammatory
processes, such as insulin resistance. This review aims to examine the literature on the
effect of helminthic infections on metabolic outcomes in humans.
Methods: Using the PRISMA protocol, we searched the literature using PubMed, MEDLINE,
and a manual review of reference lists. Human studies published in English after 1995 were
included. Four papers were included in this review. Data was extracted and a meta-analysis
was conducted using a random-effects model. Heterogeneity was assessed using Tau2 and
I2 tests.
Results: The included studies found that infection was associated with lower glucose levels,
less insulin resistance, and/or a lower prevalence of metabolic syndrome (MetS) or type 2
diabetes mellitus (T2DM). Meta-analysis showed that participants with a previous or cur-
rent helminth infection were 50% less likely to have an endpoint of metabolic dysfunction
in comparison to uninfected participants (OR 0.50; 95% CI 0.38–0.66).
Conclusion: This review has shown that helminth infections can be associated with
improvedmetabolic outcomes. Understanding of the mechanisms underlying this relation-
ship could facilitate the development of novel strategies to prevent or delay T2DM.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2102.1. Protocol and registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
2.2. Information sources and search strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
2.3. Eligibility criteria and study selection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
2.4. Data collection process and data items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211splanade,
210 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 0 ( 2 0 1 6 ) 2 0 9 –2 2 02.5. Quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
2.6. Summary measures and synthesis of results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2113. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2113.1. Study selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
3.2. Study characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
3.3. Quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
3.4. Results of individual studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2123.4.1. Glucose homeostasis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
3.4.2. Insulin resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
3.4.3. Prevalence of metabolic disease: T2DM and MetS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2143.5. Synthesis of results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2154. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2154.1. Nutrition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
4.2. Alterations to the gut microbiome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
4.3. Immunomodulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
4.4. Study limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
4.5. Conclusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219Conflicts of interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2191. Introduction
Helminths have co-evolved with humans over the centuries;
evolutionary theory would suggest some mutual benefit for
both host and parasite. Publication of the ‘‘Hygiene Hypothe-
sis” in 1989 sparked interest in the potential protective effects
of helminth infections on human disease [1] and there is now
a growing body of literature exploring the role of helminths in
prevention and management of certain autoimmune and
allergic conditions, including coeliac disease, inflammatory
bowel disease, asthma, and type 1 diabetes (T1DM) [2–4].
The apparent anti-inflammatory effect is likely to have facil-
itated the prolonged survival of the worm in individual hosts
and over our evolutionary history. Widespread interruption of
this ancient process may even elevate rates of inflammatory,
autoimmune, and allergic disease.
For the last half-century, health services around the
globe have endeavored to eradicate human helminth infec-
tions. In Australia, Aboriginal communities have been the
focus of attention, with some researchers advocating for
mass drug administration to address widespread Strongy-
loides stercoralis infection [5–8]. However, interpretation of
Australian evidence on the prevalence and clinical implica-
tions of S. stercoralis infection has attracted some contro-
versy [6–8]. This is because it is increasingly apparent
that, for the vast majority, S. stercoralis causes both a
chronic and asymptomatic infection [9]. The most serious
and fatal manifestation of the infection, however, is dis-
seminated strongyloidiasis. This has been seen in a small
number of cases globally, typically in immunosuppressed
patients [6]. Over a 10 year period in the Northern Territory,
one of the most endemic areas in Australia for the worm,
there were just six known cases of disseminated disease,
with one fatality [6].
Coinciding with increased efforts in helminth eradication,
T2DM and MetS have reached epidemic proportions acrossthe globe [10]. Metabolic diseases place huge burdens on the
health systems of both economically developed and develop-
ing societies [3]. The pathogeneses of MetS and T2DM are
complex and multifactorial, but it is clear that along with
nutritional factors, inflammation plays a critical role. Results
from multiple studies have suggested the ability of pro-
inflammatory cytokines, classically activated macrophages,
and decreased T-regulatory function to drive insulin resis-
tance in hepatic and adipose tissue [11,12]. There is also evi-
dence that demonstrates the ability of anti-inflammatory
cytokines, alternatively activated macrophages and T-
regulatory cells to protect against insulin resistance in these
tissues [11,12].
Recently published data from animal models have shown
that helminth infections can reduce insulin resistance
through modulation of immune pathways. Such observations
have prompted the hypothesis that specific helminth infec-
tions may prevent or attenuate the development of insulin
resistance in humans. A number of literature reviews have
endeavoured to piece together the growing body of epidemio-
logical, experimental, and clinical evidence to support this
hypothesis. To date, however, there has been no systematic
review or meta-analysis of this work. This paper aims to
appraise and synthesise evidence from human studies exam-
ining the effect of helminth infection on host metabolic out-
comes, including T2DM.
2. Methods
2.1. Protocol and registration
The systematic review was conducted according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analysis guidelines [13]. A review protocol was registered
with PROSPERO 2015, registration number CRD42015025486.
It is available online.
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Publications were sourced from database searches of PubMed
and MEDLINE via OvidSP; a review of reference lists of
included studies; direct contact with authors of retrieved pub-
lications; and consultation with experts in the field. One
investigator searched PubMed and MEDLINE for publications
available until February 8, 2016. The search terms used for
both databases was: (helminth OR helminths OR ‘‘soil trans-
mitted helminths” OR strongyloides OR strongyloidiasis OR
ascaris OR trichuris OR hookworm OR ‘‘necator americanus”
OR ‘‘ancylostoma duodenale” OR schistosomiasis OR schisto-
soma OR schistosome OR nematode) AND (diabetes OR ‘‘type
2 diabetes” OR ‘‘insulin resistance” OR ‘‘insulin sensitivity” OR
‘‘glucose metabolism” OR ‘‘glucose tolerance” OR ‘‘metabolic
syndrome” OR ‘‘syndrome x”) NOT (‘‘type 1 diabetes”). After
removal of duplicates, one investigator screened the titles
and abstracts of retrieved citations.
2.3. Eligibility criteria and study selection
This review focused on the influence of chronic helminth
infection on human glucose metabolism. Studies about hel-
minth metabolism of glucose, participants with symptomatic
helminth infection, those that used non-helminth organisms
or extra-intestinal helminths, and studies of T1DM were
excluded. Only papers published in English, using human par-
ticipants and published after 1995 were included. There were
no restrictions on study design, sample size, or length of
follow-up.
2.4. Data collection process and data items
One reviewer extracted relevant information from each publi-
cation using a standardised data collection form. Data items
included study design, sample characteristics (sample size,
participant characteristics, age and sex distribution of partic-
ipants), type of helminth(s), method of diagnosis of infection,
the metabolic outcome(s) assessed, results and effect esti-
mates, and control for potential confounders. Primary data
were presented in standardised units. Two additional review-
ers independently verified this process.
2.5. Quality assessment
The first author assessed the quality of the selected studies
using the National Institutes of Health’s Quality Assessment
Tool for Observational Cohort and Cross-Sectional Studies
[14]. Criteria six, seven, and 13 were not used as they were
not relevant to the cross-sectional methodology of the stud-
ies. Two additional reviewers then independently assessed
the quality of studies. Questions of publication selection
and assessment were discussed amongst the three reviewers
and consensus was achieved.
2.6. Summary measures and synthesis of results
The principal summary measure assessed in the literature
was the OR for metabolic outcomes based on infection status.ORs for varying metabolic outcomes were available from all
included studies. When available, information was also
extracted on adjustment for potential confounders, particu-
larly body mass index (BMI).
The senior author of one study was contacted to obtain
binary outcome data for the homeostatic model assessment
for insulin resistance (HOMA-IR) values for infected and
non-infected participants as this was not provided in the orig-
inal publication [15]. RevMan5.3 was used for meta-analysis
of outcomes of metabolic disturbance (hyperglycaemia,
T2DM, MetS, and insulin resistance) [16]. ORs were deter-
mined with binomial confidence intervals at 95% using the
inverse-variance method. Results were obtained using both
random- and fixed-effects models. The heterogeneity of the
data was interpreted using Tau2, to estimate the between-
study variance, and I2, to quantify inconsistencies.
3. Results
3.1. Study selection
The study selection process is outlined in Fig. 1. After removal
of duplicates, PubMed and MEDLINE database searching iden-
tified 413 papers. A search of the reference lists of included
papers identified a further 15 papers. After screening of titles
and abstracts, 412 papers were excluded. Of the remaining 16
articles, six papers were review articles without original data;
three studied the prevalence of helminth infection as an out-
come rather than as the exposure; two studied the influence
of acute infection on glucose control, and one was a study
protocol. Thus, four publications remained.
3.2. Study characteristics
Each of the four peer-reviewed articles that met the inclusion
criteria was a cross-sectional study. The characteristics are
summarised in Table 1. They came from China (n = 2)
[17,18], Indonesia (n = 1) [15], and Australia (n = 1) [19], all pub-
lished in 2013 or later. The sample sizes ranged from 259 to
3913, with a total of 6415 participants.
The helminths assessed were Schistosoma spp. (n = 2)
[17,18], S. stercoralis (n = 1) [19], and one study looked at soil-
transmitted helminths (STH) as a group, including Trichuris
trichiura, Ascaris lumbricoides, Necator americanus, Ancylostoma
duodenale, and S. stercoralis [15]. Helminth infection was diag-
nosed through a variety of mechanisms. Two studies exam-
ined current helminth infections, one using faecal
polymerase chain reaction (PCR) [15] and the other using
serum enzyme-linked immunosorbent assay (ELISA) [19].
The two Chinese papers examined previous helminth infec-
tions. One study used a combination of self-reported infection
and medication history, cross-referenced with a local infec-
tious disease registry [17]; and the other used liver ultrasound
to detect evidence of previous schistosomal infection (PSI)
[18].
There were different outcome measures for each study,
but most assessed one or more indicators of glucose metabo-
lism. They included fasting blood glucose (FBG) (n = 3)
[15,17,18], post-prandial blood glucose (PBG) (n = 1) [17],
Records identified through 
PubMed search
(n = 326)
Additional records identified 
through reference lists
(n = 15)
Records after duplicates removed
(n = 413)
Titles and abstracts screened
(n = 428)
Records excluded
(n = 412)
Full-text articles assessed for 
eligibility
(n = 16)
Full-text articles excluded 
(n = 12)
Review paper (n=6)
Helminth infection was studied as the 
outcome not the exposure (n=3)
Active helminth infection (n=2)
Study protocol (n=1)
Studies included in 
qualitative synthesis
(n = 4)
Studies included in meta-
analysis
(n = 4)
Records identified through 
MEDLINE search
(n = 169)
Fig. 1 – PRISMA flow diagram of selection process.
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(n = 1) [15], HOMA-IR insulin resistance index (n = 2) [15,17],
prevalence of T2DM (n = 2) [17,19] and prevalence of MetS
(n = 2) [17,18]. T2DM was defined by one Chinese study [17]
using theWorld Health Organisation’s criteria (fasting glucose
P7.0 mmol/L or two-hour glucose P11.1 mmol/L) [20]. The
Australian study used similar diagnostic criteria
(HbA1cP 6.5%, random blood glucose > 11.1 mmol/L; or fast-
ing glucose > 7.0 mmol/L) [19]. MetS was defined using two
different diagnostic criteria, one study used the National
Cholesterol Education Program’s criteria (NCEP-ATP III) [21]
and the other used the International Diabetes Federation cri-
teria [22].
There was no information available about previous anti-
helminth treatment status of the participants in any of the
four studies. Two papers treated infected participants with
anti-helminth agents after metabolic outcomes had been
measured.
3.3. Quality assessment
Table 2 summarises the quality assessment of the included
human studies. Overall, their quality was acceptable. Two
were judged to be of ‘fair’ quality [17,18] and two ‘good’
[15,19]. All studies clearly stated their research objectives
and defined populations being studied. Exposed and control
subjects were recruited from the same population over the
same time period in all studies. Inclusion and exclusion crite-ria were well defined and appropriately applied. The partici-
pation rate of eligible subjects was greater than 50% in three
of the studies; however, due to a low prevalence of previous
schistosomal infection and low prevalence of diabetes in
younger populations, one study only analysed data from par-
ticipants over 60 years of age, potentially introducing selec-
tion bias [17]. Sample sizes were clearly stated in all studies;
however only one provided a justification for the sample size
[17]. The definition of a case of previous helminth infection
varied across the studies, with two using objective methods
for diagnosis (PCR and ELISA testing) [15,19] and two using
subjective measures (self-report and ultrasound findings)
[17,18]. One study repeated the ELISA after 287 days for the
participants with initially negative results [19]. None of the
other studies assessed the exposure more than once. The out-
come measures varied between studies, but all used clearly
defined, universally accepted methods for assessment of both
exposure and control groups. None reported a loss to follow-
up. All four conducted multivariate analyses of results to
adjust for potential confounding variables, including age
and BMI.
3.4. Results of individual studies
All the studies found that previous helminth infection was
associated with improved glucose homeostasis, reduced insu-
lin resistance, and/or lower prevalence of T2DM or MetS. The
results are summarised in Tables 3 and 4.
Table 1 – Characteristics of studies.
Study Study design Participant details Exposure Outcomes
Type Sample
size
Helminth Method of
diagnosis
Primary outcomes Description of diagnosis Secondary
outcomes
Chen China,
2013 [17]
Cross-sectional 3913 Men and women aged
60 years and older in two
communities in Jiading
County, China
Schistosomal
spp.
Self-reported
history and
medication
history, cross-
referenced with
local government
registry data from
1989
MetS prevalence NCEP criteria HOMA-IR
FBG
PBG
HbA1c
T2DM prevalence WHO criteria
Shen China,
2015 [18]
Cross-sectional 1597 Healthy men, >45 years
presenting at a health
unit between April and
June 2013 in an area in
China previously
endemic for S japonicum.
Excluded those with
known liver disease or
heavy alcohol
consumption
Schistosomal
spp.
Liver U/S showing
evidence of
chronic infection
MetS prevalence IDF criteria FBG
Wiria Indonesia,
2015 [15]
Cross-sectional 646 Community members
>18 years who had
participated in the
ImmunoSPIN project
with available stool
samples. Nangapanda,
an area highly endemic
for STH
T. trichiura
A. lumbricoides
N. americanus
A. duodenale
S. stercoralis
Microscopy
PCR
PCR
PCR
PCR
HOMA-IR Fasting serum
insulin  fasting glucose/
22.5
FBG
Fasting serum
insulin
Hays Australia,
2015 [19]
Cross-sectional 259 Patients attending a
clinic in three Aboriginal
communities in the
Kimberly region,
Australia
S. stercoralis ELISA
Positive > 0.30
T2DM Defined by: HbA1c > 6.5%
11.1 mmol/L
FBG > 7.0 mmol/L at the
time or in the past in
patients with known
T2DM
MetS: metabolic syndrome; T2DM: type 2 diabetes mellitus; NCEP: National Cholesterol Education Program Adult Treatment Panel III criteria (three or more of: blood pressure > 130/85; waist
circumference (WC) > 102 cm (men) or 88 cm (women); triglycerides (TG) > 1.69 mmol/L, high density lipoprotein cholesterol (HDL-C) < 1.03 mmol/L (men) or < 1.29mml/L (women); fasting blood
glucose > 6.1 mmol/L); WHO: World Health Organisation criteria (fasting blood glucose > 7.0 mmol/L; post-prandial blood glucose > 11.1 mmol/L; self-reported diagnosis of diabetes as diagnosed by a
physical; or use of antidiabetic medication); HOMA-IR: homeostatic model assessment of insulin resistance; FBG: fasting blood glucose; PBG: post-prandial blood glucose; HbA1c: glycated hae-
moglobin; U/S: ultrasound; IDF: International Diabetes Federation criteria (central obesity (WC > 90 cm) and any two of TG > 1.7 mmol/L; HDL-C < 1.0 mmol/L or treatment of dyslipidaemia; systolic
blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg; or FBG > 5.6 mmol/L or previous T2DM diagnosis); STH: soil transmitted helminths; PCR: polymerase chain reaction; ELISA: enzyme
linked immunosorbent assay; BSL: blood sugar level.
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Table 2 – Quality of studies using the NIH’s quality assessment of cohort and cross-sectional studies.
Chen,
2013 [17]
Hays,
2015 [19]
Shen,
2015 [18]
Wiria,
2015 [15]
1. Was the research question or objective in this paper
clearly stated?
Yes Yes Yes Yes
2. Was the study population clearly specified and defined? Yes Yes Yes Yes
3. Was the participation rate of eligible persons at least
50%?
No NR Yes No
4. Were all the subjects selected or recruited from the
same or similar populations (including the same time
period)? Were inclusion and exclusion criteria for being in
the study prespecified and applied uniformly to all
participants?
Yes Yes Yes Yes
5. Was a sample size justification, power description, or
variance and effect estimates provided?
Yes No No No
6. For the analyses in this paper, were the exposure(s) of
interest measured prior to the outcome(s) being
measured?
N/A N/A N/A N/A
7. Was the timeframe sufficient so that one could
reasonably expect to see an association between exposure
and outcome if it existed?
N/A N/A N/A N/A
8. For exposures that can vary in amount or level, did the
study examine different levels of the exposure as related
to the outcome (e.g. categories of exposure, or exposure
measured as continuous variable)?
No Yes N/A Yes
9. Were the exposure measures (independent variables)
clearly defined, valid, reliable, and implemented
consistently across all study participants?
No Yes No Yes
10. Was the exposure(s) assessed more than once over
time?
No No No No
11. Were the outcome measures (dependent variables)
clearly defined, valid, reliable, and implemented
consistently across all study participants?
Yes Yes Yes Yes
12. Were the outcome assessors blinded to the exposure
status of participants?
Yes Yes NR Yes
13. Was loss to follow-up after baseline 20% or less? Yes Yes Yes Yes
14. Were key potential confounding variables measured
and adjusted statistically for their impact on the
relationship between exposure(s) and outcome(s)?
Yes Yes Yes Yes
Overall quality rating (good, fair, or poor) Fair Good Fair Good
NR: not reported; N/A: not applicable.
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Three studies assessed the association between helminth
infection and glucose homeostasis through measurement of
FBG, PBG, and/or HbA1c [15,17,18]. Three studies that mea-
sured FBG found that participants with previous helminth
infection had lower mean FBG levels than uninfected partici-
pants. This was statistically significant in a cross-sectional
study from China [17]. This study also investigated the effect
of helminth infection on PBG and demonstrated that partici-
pants with previous helminth infection had significantly
lower PBG than uninfected groups. Additionally, this study
showed that infected groups had a significantly lower HbA1c
in comparison to uninfected groups.
3.4.2. Insulin resistance
Insulin resistance was assessed in two studies through mea-
surements of HOMA-IR and/or fasting serum insulin con-
centration [15,17]. HOMA-IR is a validated measure of
insulin resistance. It is calculated by multiplying the fasting
serum insulin (mU/L) by fasting blood glucose (mmol/L) andthen dividing the result by 22.5. Lower HOMA-IR values indi-
cate less insulin resistance [23]. Both studies showed signif-
icantly lower HOMA-IR values in infected groups compared
to uninfected groups. Also of note, Wiria et al. found that
insulin resistance was incrementally reduced with every
additional STH species infection [15]. In this study partici-
pants with previous STH infections tended to have lower
fasting serum insulin levels, though this was not a signifi-
cant result.
When analysing the ORs for insulin resistance, it should be
noted that the two studies used different definitions of an ‘ab-
normal’ HOMA-IR result. Chen’s study defined insulin resis-
tance as HOMA-IR values of higher than 2.50, whereas in
Wiria’s study the authors used the 90th percentile to mark
an abnormal value, which was given as 1.54.
3.4.3. Prevalence of metabolic disease: T2DM and MetS
Table 4 shows the prevalence of T2DM assessed in two stud-
ies, both of which showed a significant protective association
[17,19]. ORs, when adjusted for BMI, were 0.47 (0.32–0.69) [17]
Table 3 – Primary results.
Study Measure of glucose or insulin homeostasis Prevalence
FBG PBG HbA1c in NGSP % Fasting serum
insulin
HOMA-IR T2DM MetS
(mmol/L) (mmol/L) (IFCC mmol/mol) (pmol/L) (units) (%) (%)
Chen China, 2013 [17] Infected
(n = 463)
5.50** 8.03** 5.8*
(40)
– 1.20** 14.90** 14.00**
Uninfected
(n = 3450)
5.70** 9.23** 5.9*
(41)
 1.73** 25.40** 35.00**
Hays Australia, 2015 [19] Infected
(n = 92)
     34.78** 
Uninfected
(n = 167)
     59.28** 
Shen China, 2015 [18] Infected
(n = 465)
6.21+      18.28**
Uninfected
(n = 1132)
6.38+      34.01**
Wiria Indonesia, 2015 [15] Infected
(n = 316)
5.88+   45.00+ 0.81*  
Uninfected
(n = 161)
5.92+   49.50+ 0.97*  
FBG: fasting blood glucose; PBG: post-prandial blood glucose; HbA1c: glycated haemoglobin; NGSP: National Glycohemoglobin Standardization
Program; IFCC: International Federation of Clinical Chemistry; HOMA-IR: homeostatic model assessment of insulin resistance; T2DM: type 2
diabetes mellitus; MetS: metabolic syndrome.
+ p > 0.05.
* p < 0.05.
** p < 0.01.
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with previous helminth infection were less likely to have
MetS, with adjusted ORs of 0.35 (0.25–0.49) [17] and 0.67
(0.48–0.93) [18]. The adjusted OR for the prevalence of MetS
in Chen’s paper did not include an adjustment for BMI, a
potentially confounding variable [17].
3.5. Synthesis of results
A meta-analysis was completed using the available data for
metabolic end-points, as is shown in Fig. 2. The OR for hyper-
glycaemia (defined as FBGP 5.6 mmol/L) in participants with
previous helminth infection was 0.72 (0.59, 0.87) (Tau2: 0.0, I2:
0%). The OR for the prevalence of T2DM was 0.47 (0.35, 0.63)
(Tau2: 0.01, I2: 21%). The OR for the prevalence of MetS was
0.36 (0.26, 0.52) (Tau2: 0.05, I2: 71%). Of the two studies which
reported HOMA-IR as an outcome, only one had results that
were able to be used in a meta-analysis [15]. These results
defined insulin resistance as a HOMA-IR score above the
90th percentile. The OR for this outcome was 0.60 (0.32,
1.10). When abnormal metabolic outcomes from all studies
were combined and assessed using a random-effects model,
the OR was 0.50 (0.38, 0.66) (Tau2: 0.10, I2: 80%). This result
did not significantly differ when using a fixed-effects model
(OR 0.49; CI 0.44–0.55). As can be seen in Fig. 2, the subgroups
within the meta-analysis are not mutually exclusive. For
example, Chen’s study includes results for the prevalence of
T2DM and MetS. To address this, the analysis was repeated
excluding each of the overlapping data sets. The overall OR
did not change substantially with these exclusions. The OR
rangewas from 0.47 to 0.56 with confidence intervals between
0.35 and 0.70 in all variations.4. Discussion
There was a protective association between helminth infec-
tion and adverse metabolic outcomes in each of the included
studies. Our meta-analysis found that participants with a pre-
vious or current helminth infection were 50% less likely to
have an outcome of metabolic dysfunction in comparison to
participants without evidence of helminth infection. As these
were all cross-sectional studies, causality cannot be inferred.
However, when reassessed against Bradford-Hill’s ‘nine view-
points’ the collective results offer some causal insight.
According to Bradford-Hill, assessment of causality is facili-
tated by taking into account the following: the strength of
association, consistency of effect, available experimental evi-
dence, a dose-response relationship, timing (the cause must
precede the effect), coherence, biologic credibility, specificity,
and analogy [24].
All studies included in the review showed at least one sig-
nificant association between infection and a metabolic out-
come, with several showing protective associations for
multiple outcomes. The individual measures of effect, as seen
in Table 4, demonstrate consistent ORs in favour of a protec-
tive association. In the meta-analysis, the combined random-
effects OR of 0.50 (0.38, 0.66) demonstrates a strong protective
association between helminth infections and metabolic out-
comes. The results were consistent across heterogeneous
populations, across different countries, and when studying
different helminths.
While these human studies are observational, experimen-
tal evidence could test the theory in a more robust way to
shed light on potential mechanisms. There is a growing body
of evidence from animal research supporting the hypothesis
T ble 4 – Odds ratios.
tudy Measure of glucose or insulin homeostasis Prevalence Comments
Hyperglycaemia
(FBGP 5.6 mmol/L)
Insulin resistance
(Abnormal HOMA-IR)
T2DM MetS
hen China, 2013 [17] Unadjusted OR
(CI, 95%)
 0.39
(0.30–0.51)**
0.52
(0.39–0.67)**
0.30
(0.23–0.40)**
For insulin resistance
and T2DM adjustment
was for age, sex, BMI,
physical activity, family
history of T2DM, and
education level. The OR
for MetS was adjusted for
the above factors
excluding BMI. An
abnormal HOMA-IR was
defined as >2.50
Adjusted OR
(CI, 95%)
 0.59
(0.40–0.85)**
0.47
(0.32–0.69)**
0.35
(0.25–0.49)**
hen China, 2015 [18] Unadjusted OR
(CI, 95%)
0.68
(0.55–0.86)**
  0.43
(0.33–0.57)**
Adjustment was for age
and BMI
Adjusted OR
(CI, 95%)
0.87
(0.68–1.10)+
  0.67
(0.48–0.93)*
iria Indonesia, 2015 [15] Unadjusted OR
(CI, 95%)
0.83
(0.57, 1.22)^
0.60
(0.32, 1.10)^
  Abnormal HOMA-IR was
a score >90th percentile
or >1.54 units.
ays Australia, 2015 [19] Unadjusted OR
(CI, 95%)
  0.37
(0.22–0.62)**
 Adjustment was for age,
BMI, systolic BP and
triglyceridesAdjusted OR
(CI, 95%)
  0.39
(0.23–0.67)**

R: odds ratio; CI: confidence interval; FBG: fasting blood glucose; HOMA-IR: homeostatic model assessment of insulin resistance; T2DM: type 2 diabetes mellitus; MetS: metabolic syndrome; BMI:
ody mass index; BP: blood pressure.
OR was provided separately by the authors, no p-value given.
p > 0.05.
p < 0.05.
p < 0.01.
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Fig. 2 – A meta-analysis of metabolic end-points.
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disease. Mouse studies have shown that experimental infec-
tion with helminths can result in reduced fasting glucose con-
centrations, decreased fasting insulin concentrations,
improved glucose and insulin tolerance, and less insulin
resistance in comparison to non-infected controls [25–29].
With respect to ‘biological gradient’, Bradford-Hill nomi-
nated dose-response as a key factor in assessing causation
[24]. The included study by Wiria et al. found that an increas-
ing number of different helminth infections correlated with
incremental reductions in insulin resistance [15]. It is plausi-
ble that insulin resistance is reduced in a dose-dependent
manner reflected by the infectious load of the worms, but this
has not yet been investigated.
Temporality is difficult to establish in cross-sectional stud-
ies. Nevertheless, three studies had sufficient chronological
data to provide some insight into exposure and outcome.
Chen and Shen’s studies were located in areas that were
highly endemic for Schistosoma spp. 30 years ago but are
now non-endemic areas [17,18]. Chen et al. defined a PSI case
using a self-reported history of infection, cross-referenced
with a government registry from 1989 [17]. Shen et al. looked
at ultrasound features of chronic schistosomal liver disease
[18]. Hays et al. used ELISA for diagnosis of S. stercoralis and
followed participants with negative results over the course
of nine months. They found just three new infections in this
period, indicating that it is likely that the majority of partici-pants with positive ELISA results had long-standing, rather
than recent, S. stercoralis infections [19].
This review has identified a protective association
between previous helminth infections and metabolic disease.
Three plausible mechanisms to explain this association are
discussed below. It is likely that these mechanisms are inter-
active rather than mutually exclusive.
4.1. Nutrition
A nutrition-based hypothesis is that the helminth causes
depletion of human energy sources resulting in weight loss,
leading to improved metabolic outcomes. Infection was asso-
ciated with a significantly lower BMI in three studies, but the
protective effect of helminth infection onmetabolic outcomes
persisted in all studieswhen adjusted for BMI [15,17–19]. Addi-
tionally, recent mice experiments have shown improved
metabolic outcomes in mice exposed to just proteins of hel-
minths (lacto-N-fucopentaose III and Schistosoma mansoni sol-
uble egg antigens) without the parasitic effects of the whole
organism [25,26]. Thus it is unlikely that nutritional depletion
alone is responsible for improved glucose metabolism.
4.2. Alterations to the gut microbiome
Helminths may improve insulin sensitivity in the host
through manipulation of the human gut microbiome. Animal
218 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 0 ( 2 0 1 6 ) 2 0 9 –2 2 0studies of autoimmune disease have shown a correlation
between disease activity, helminth infection and parallels in
the qualitative and quantitative diversity of the gut micro-
biome. So far, these studies have focused on idiopathic
chronic diarrhoea, ulcerative colitis, and coeliac disease [30].
A number of observational studies and one randomised con-
trolled trial have shown that changes to the gut microbiome
can improve insulin resistance [31–33]. The relationship
between helminths, the microbiome and metabolic outcomes
has yet to be studied.
4.3. Immunomodulation
It is postulated that helminth infections may exert an evolu-
tionary advantage by maintaining host immune tolerance
through immune-modulation pathways. A recently published
paper studied the cytokine profile of asymptomatic infected
individuals and found that they had significantly lower circu-
lating levels of pro-inflammatory cytokines and significantly
higher levels of anti-inflammatory cytokines [34]. The worms’
anti-inflammatory properties may result in reduced insulin
resistance. This hypothesis is summarised in Fig. 3. Classi-
cally activated macrophages (CAMs) are typically increased
transiently in response to bacterial and viral infections. They
are also chronically raised with obesity and insulin resistance
[35]. As is shown in Fig. 3, high levels of related pro-expr
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Fig. 3 – A potential immunomodulatory explanation of tinflammatory cytokines (TNF-a, IL-1B, and IL-6) reduce the
expression of glucose transporters and inhibit the activity of
insulin receptors thus impairing insulin sensitivity [36]. Alter-
natively, helminth infections induce the production of Th2
cells, T regulatory cells, and eosinophils. This skews macro-
phage polarisation in adipose tissue away from CAMs towards
alternatively activated macrophages (AAMs) [35]. A shift
towards AAMs is accompanied by the production of anti-
inflammatory cytokines, particularly IL-4, IL-5, IL-10, IL-13,
and TGF-B [35,36]. These cytokines also inhibit pro-
inflammatory responses from CAMs. Thus, through the Th2
pathway, helminths may promote insulin sensitivity to pre-
vent the development of MetS and T2DM.
4.4. Study limitations
Only one author of this review conducted the initial literature
search and data extraction. Thus, there is a potential source
of error in the process. Selection bias is a potential issue in
three of the studies. Wiria et al. used participants who had
previously provided stool samples as part of the ImmunoSPIN
trial [15]. Chen et al. only included an analysis of participants
over the age of 60 years due to a low prevalence of PSI and
T2DM in younger populations [17]. Shen et al. defined a PSI
based on subjective ultrasound findings and would have
excluded participants with a history of infection who didClassically 
activated 
macrophages
TNF-a 
IL-1B 
IL-6
Reduces GLUT-4 
ession in muscle & fat
Inhibits insulin receptor 
tyrosine kinase activity
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he effect of helminth infection on insulin resistance.
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outcome of glucose metabolism has shortcomings, with
known variation dependent on age, time of day, activity
levels, alcohol intake, and duration of fast [37].
There were only a small number of studies available for
meta-analysis. Two assessed previous infection whilst two
assessed likely current helminth infection. There was no
obvious difference in outcome between previous or current
infections. With the meta-analysis, a combined outcome
was used because, although there were variations in out-
comes reported, they all pointed to the metabolic syndrome.
Due to the small number of published studies on the subject
matter, the evidence for each individual outcome measure
was limited. It is likely that the case would be better made
with meta-analysis of individual patient data.
It is difficult to interpret the estimates of heterogeneity
produced by RevMan5.3. The confidence intervals for hetero-
geneity estimates are not included in the software’s output. It
is possible that the high heterogeneity score given by RevMan
5.3 reflects the multiple measures in the combined metabolic
syndrome endpoint. Additionally, the chi-squared and I2 tests
have well-recognised shortcomings [38]. In spite of this, the
consistency of results across these different study popula-
tions and measures suggest a real association.
The random-effects model used should provide more con-
servative estimates with wider confidence intervals [39]. Rev-
Man5 uses the DerSimonian–Laird method for random-
effects analyses. This method has widely recognised faults,
including the production of narrow confidence intervals and
biased estimates [40]. Though the method has been recog-
nised as one of the optimal methods of analyses when exam-
ining less than five studies [39].
It is expected that this study’s conclusions will be further
validated as more studies are published examining the poten-
tial metabolic protective effects of helminth infection.4.5. Conclusion
To our knowledge, this is the first systematic review and
meta-analysis on the effect of helminth infections on meta-
bolic disease. It has found a strong protective association
between helminth infections and metabolic outcomes. With
a greater understanding of the pathways underlying this rela-
tionship novel therapeutic strategies can potentially be devel-
oped to prevent or delay the onset of T2DM.Conflicts of interests
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